Center for Obsessive-Compulsive Treatment and Related Disorders

Current Studies

We are currently recruiting participants for a wide range of research studies! Our research work is funded in large part by the National Institutes of Health (NIMH) and by private foundations. If you are interested in participating in one of our research studies, please call (646) 774-8062 to speak with a research coordinator. We will offer you a confidential screening and evaluation to determine whether you are eligible for one of our studies. Any treatment you receive as part of your study participation is provided at no cost to you.

  • A Randomized, Double-Blind, Placebo-Controlled Trial of Trigriluzole for OCD

    Principal Investigator

    Helen Blair Simpson, MD, PhD
    For this study, eligible participants will be asked questions about their symptoms and complete a medical evaluation. You will receive a medication, and be monitored by medical professionals. You will also be asked to complete questionnaires. The purpose of this study is to assess to evaluate a medication for the treatment of OCD.

  • Cannabinoids and OCD

    Principal Investigator

    Helen Blair Simpson, MD, PhD
    The purpose of this pilot research study is to test the effects of a medication called nabilone (Cesamet) in adults with obsessive-compulsive disorder (OCD). Participants will receive either nabilone on its own, or nabilone in combination with a form of cognitive-behavioral therapy (CBT) called exposure and response prevention (EX/RP). Nabilone is a synthetic cannabinoid and acts on the brain's "endocannabinoid system," which has been hypothesized to play a role in OCD. Nabilone is approved by the FDA for the treatment of chemotherapy-induced nausea and vomiting.